3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell signaling

BMC Complementary and Alternative Medicine

Volumn 17, Issue 1, 2017, Pages

  Telerman, Alona ^a   Ofir, Rivka ^b   Kashman, Yoel ^c   Elmann, Anat ^a  

^a VOLCANI CENTER   (Israel)

^b The Dead Sea and Arava Science Center   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

3,5,4' trihydroxy 6,7,3' trimethoxyflavone; Achillea fragrantissima; Alzheimer's disease; Amyloid beta; Flavonoids; Mitogen activated protein kinases; Neurons

Indexed keywords

3,5,4' TRIHYDROXY 6,7,3' TRIMETHOXYFLAVONE; AMYLOID BETA PROTEIN[25-35]; CRYSTAL VIOLET; DICHLOROFLUORESCEIN; FLAVONE DERIVATIVE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ANTIOXIDANT; PLANT EXTRACT;

ACHILLEA; ACHILLEA FRAGRANTISSIMA; ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LEVEL; CELL VIABILITY; CULTURE MEDIUM; CYTOTOXICITY; DRUG ACTIVITY; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; IMMUNOCYTOCHEMISTRY; INTRACELLULAR SIGNALING; MOUSE; N2A CELL LINE; NERVE CELL NECROSIS; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; APOPTOSIS; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACHILLEA; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; APOPTOSIS; CELL LINE; CELL SURVIVAL; FLAVONES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHOSPHORYLATION; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85021217919     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-017-1840-y     Document Type: Article

References (37)

1. Lloret A, Fuchsberger T, Giraldo E, Vina J. Molecular mechanisms linking amyloid beta toxicity and tau hyperphosphorylation in Alzheimer's disease. Free Radic Biol Med. 2015;83:186-91.
2. Liu J, Yang B, Ke J, Li W, Suen WC. Antibody-based drugs and approaches against amyloid-beta species for Alzheimer's disease immunotherapy. Drugs Aging. 2016;33(10):685-97.
3. Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease. Prog Neurobiol. 2016;147:1-19.
4. Kim MH, Kim SH, Yang WM. Mechanisms of action of phytochemicals from medicinal herbs in the treatment of Alzheimer's disease. Planta Med. 2014;80(15):1249-58.
5. Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, et al. Recent Updates in the Treatment of Neurodegenerative Disorders Using Natural Compounds. Evid-Based Compl Alt. 2014;979730 http://dx.doi.org/10.1155/2014/979730
6. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibiotory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol. 1989;38(11):1763-9.
7. Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, et al. Anti-parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol. 2012;139(3):698-711.
8. Williams RJ, Spencer JP. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med. 2012;52(1):35-45.
9. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004;36(5):592-604.
10. Serafini M, Peluso I, Raguzzini A. Session 1: antioxidants and the immune system flavonoids as anti-inflammatory agents. P Nutr Soc. 2010;69(3):273-8.
11. Kumar S, Pandey AK. Chemistry and Biological Activities of Flavonoids: An Overview. Sci World J. 2013; 2013: Article ID 162750.doi: 10.1155/2013/162750.
12. Baptista FI, Henriques AG, Silva AMS, Wiltfang J, Silva OABDE. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem Neurosci. 2014;5(2):83-92.
13. Orhan IE, Daglia M, Nabavi SF, Loizzo MR, Sobarzo-Sanchez E, Nabavi SM. Flavonoids and dementia: an update. Curr Med Chem. 2015;22(8):1004-15.
14. Elmann A, Telerman A, Mordechay S, Erlank H, Rindner M, Ofir R, et al. 3,5,4'-Trihydroxy-6,7,3'-trimethoxyflavone protects astrocytes against oxidative stress via interference with cell signaling and by reducing the levels of intracellular reactive oxygen species. Neurochem Int. 2014;78:67-75.
15. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem. 1989;182(1):16-9.
16. Wojtunik-Kulesza KA, Oniszczuk A, Oniszczuk T, Waksmundzka-Hajnos M. The influence of common free radicals and antioxidants on development of Alzheimer's disease. Biomed Pharmacother. 2016;78:39-49.
17. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec. 2009;292(12):1902-13.
18. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res. 2011;1417:127-36.
19. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci. 2002;22(9):3376-85.
20. Echeverria V, Ducatenzeiler A, Dowd E, Janne J, Grant SM, Szyf M, et al. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neurosci. 2004;129(3):583-92.
21. Braithwaite SP, Schmid RS, He DN, Sung MLA, Cho S, Resnick L, et al. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol Dis. 2010;39(3):311-7.
22. Tare M, Modi RM, Nainaparampil JJ, Puli OR, Bedi S, Fernandez-Funez P, et al. Activation of JNK Signaling Mediates Amyloid-beta-Dependent Cell Death. Plos One. 2011;6(9)
23. Andrade JP, Assuncao M. Protective effects of chronic green tea consumption on age-related neurodegeneration. Curr Pharm Des. 2012;18(1):4-14.
24. Ghasemi R, Moosavi M, Zarifkar A, Rastegar K, Maghsoudi N. The interplay of Akt and ERK in a beta toxicity and insulin-mediated protection in primary hippocampal cell culture. J Mol Neurosci. 2015;57(3):325-34.
25. Ayaz M, Junaid M, Ahmed J, Ullah F, Sadiq A, Ahmad S, et al. Phenolic contents, antioxidant and anticholinesterase potentials of crude extract, subsequent fractions and crude saponins from Polygonum hydropiper L. BMC Complement Altern Med. 2014;14:145.
26. Ahmad S, Ullah F, Ayaz M, Sadiq A, Imran M. Antioxidant and anticholinesterase investigations of Rumex hastatus D. Don: potential effectiveness in oxidative stress and neurological disorders Biol Res. 2015;48:20.
27. Bowirrat A, Yassin M, Abir M, Bisharat B. Armaly Z. Traditional and Modern Medicine Harmonizing the Two Approaches in the Treatment of Neurodegeneration. In: Complementary Therapies for the Contemporary Healthcare. edn. Novi Sad: InTech Prepress. 2012:181-212.
28. Annweiler C, Beauchet O. Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging. 2012;29(2):81-91.
29. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Preti D, et al. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg Med Chem Lett. 2008;16(10):5367-76.
30. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, et al. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med. 2002;33(12):1693-702.
31. Ferruzzi MG, Lobo JK, Janle EM, Cooper B, Simon JE, Wu QL, et al. Bioavailability of Gallic acid and Catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J Alzheimers Dis. 2009;18(1):113-24.
32. Matias I, Buosi AS, Gomes FCA. Functions of flavonoids in the central nervous system: astrocytes as targets for natural compounds. Neurochem Int. 2016;95:85-91.
33. Jager AK, Saaby L. Flavonoids and the CNS. Molecules. 2011;16(2):1471-85.
34. Kam TI, Gwon Y, Jung YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. Cell Mol Life Sci. 2014;71(24):4803-13.
35. Murakami A, Ohnishi K. Target molecules of food phytochemicals: food science bound for the next dimension. Food Funct. 2012;3(5):462-76.
36. Hou DX, Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antiox Redox Signal. 2010;13(5):691-719.
37. Mandour MA, Al-Shami SA, Al-Eknah MM, Hussein YA, El-Ashmawy IM. The acute and long-term safety evaluation of aqueous, Methanolic and Ethanolic extracts of Achillea Fragrantissima. Afr J Pharm Pharmacol. 2013;7(32):2282-90.